Erudio Healtherudio.com
Drug
Mirvetuximab soravtansine trials: what clinicians said in public
No HCP commentary report on a trial studying mirvetuximab soravtansine yet. Erudio has found public clinician commentary on 3 clinical trials studying mirvetuximab soravtansine: FORWARD I, MIRASOL and SORAYA. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| MIRASOL NCT04209855 · AbbVie DeepView → | platinum-resistant ovarian cancer with high FRα expression | Phase 3 | Deep | View | |||
| SORAYA NCT04296890 · ImmunoGen, Inc. DeepView → | FRα-high platinum-resistant ovarian cancer | Phase 3 | Deep | View | |||
| FORWARD I NCT02631876 · ImmunoGen, Inc. FocusedView → | folate receptor alpha-positive platinum-resistant epithelial ovarian cancer | Phase 3 | Focused | View | |||